Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00062244 · ClinicalTrials.gov registry record · Phase 1
Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
NCT00062244: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00062244 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 58 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00062244, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
This phase I/II trial is studying the side effects and best dose of oblimersen and to see how well it works in treating patients with relapsed or refractory Waldenstrom's macroglobulinemia. Biological therapies such as oblimersen may interfere with the growth of the cancer cells and slow or stop the growth of Waldenstrom's macroglobulinemia.
Interventions
- BIOLOGICAL oblimersen sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2003-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00062244
The ClinicalTrials.gov registry entry for NCT00062244 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which oblimersen sodium is the first listed.
NCT00062244 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00062244 about?
NCT00062244 is a clinical study titled "Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia". This phase I/II trial is studying the side effects and best dose of oblimersen and to see how well it works in treating patients with relapsed or refractory Waldenstrom's macroglobulinemia. Biological therapies such as oblimersen may interfere with the growth of the cancer cells and slow or stop the...
What is the current status of trial NCT00062244?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2003-05.
What interventions are being tested in trial NCT00062244?
The interventions under investigation include: oblimersen sodium (BIOLOGICAL).
Who is sponsoring clinical trial NCT00062244?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.